Glossary term
Contingent Value Rights (CVR)
Contingent value rights are deal securities or contractual rights that pay holders if specified post-closing milestones or events occur.
Updated
Read time
What Are Contingent Value Rights (CVRs)?
Contingent value rights, or CVRs, are deal securities or contractual rights that pay holders if specified post-closing milestones or events occur. They are often used in mergers and acquisitions when buyer and seller disagree about the value of uncertain future outcomes.
A CVR lets the buyer avoid paying full value upfront for an uncertain asset, while giving sellers or target shareholders a possible future payment if the asset performs. The right may be tied to drug approvals, sales milestones, litigation outcomes, asset sales, regulatory events, or other measurable triggers.
Key Takeaways
- CVRs provide possible future payments tied to specified milestones.
- They are common when deal value depends on uncertain post-closing events.
- CVRs can be transferable or nontransferable depending on the agreement.
- The payout depends on contract terms, timing, definitions, and enforcement rights.
- Investors should not treat a CVR as guaranteed merger consideration.
How CVRs Work
In an acquisition, the buyer may pay cash or stock at closing and issue CVRs to target shareholders. The CVR agreement defines the milestones, payout amounts, deadlines, calculation methods, rights agent, reporting duties, and dispute process. If the milestone is met, holders receive the specified payment. If it is not met, the CVR may expire worthless.
Biotechnology deals often use CVRs because a drug candidate may be valuable if approved but worth far less if trials fail or regulators reject it. A CVR can bridge that valuation gap without forcing one side to concede the full uncertainty at closing.
What Determines CVR Value
A CVR's value depends on the probability of the milestone, expected payout, time to payment, legal enforceability, transferability, taxes, and counterparty credit. A high headline payout may be worth little if the milestone is unlikely, loosely defined, or far in the future.
Investors also need to read the buyer's obligations. Some CVRs require commercially reasonable efforts. Others give the buyer broader discretion. That difference can matter because the buyer may control development spending, regulatory strategy, or asset sales after the deal closes.
Transferable Versus Nontransferable CVRs
Type | Investor effect |
|---|---|
Transferable CVR | May trade separately, creating a market price |
Nontransferable CVR | Held by original recipients, often with limited liquidity |
Transferability affects liquidity and valuation. A traded CVR can have visible pricing, though the market may be thin. A nontransferable CVR may be harder to value because holders cannot easily sell it.
Risks and Misreadings
CVRs are contingent. They can expire worthless even when the underlying deal closes successfully. Milestone definitions can be technical, and small wording differences can decide whether payment is owed. Holders may also have limited ability to force business decisions that would improve milestone odds.
Tax treatment can be complicated because the CVR may be part of merger consideration and may produce later payments. Investors should read the merger documents rather than relying on the headline deal price alone.
Example
Suppose a buyer acquires a biotechnology company with a drug candidate still awaiting regulatory approval. The buyer pays $20 per share at closing and grants a CVR that pays another $3 per share if the drug is approved by a stated deadline. If approval occurs on time and the agreement conditions are met, holders receive the payment. If not, the CVR may expire with no value.
The example shows why CVRs are often priced like contingent claims. The headline maximum payment is less important than the probability, timing, and enforceability of the milestone.
The Bottom Line
Contingent value rights are future-payment rights tied to specific events after a transaction. They can bridge valuation uncertainty in mergers, but their value depends on contract terms, milestone probability, transferability, and the buyer's post-closing obligations.